Bond Celgen Corporation 3.9% ( US151020BB94 ) in USD
| Issuer | Celgen Corporation |
| Market price | |
| Country | United States
|
| ISIN code |
US151020BB94 ( in USD )
|
| Interest rate | 3.9% per year ( payment 2 times a year) |
| Maturity | 19/02/2028 |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 2 000 USD |
| Total amount | 1 500 000 000 USD |
| Cusip | 151020BB9 |
| Standard & Poor's ( S&P ) rating | A+ ( Upper medium grade - Investment-grade ) |
| Moody's rating | N/A |
| Next Coupon | 20/02/2026 ( In 66 days ) |
| Detailed description |
Celgene Corporation was a biopharmaceutical company acquired by Bristol Myers Squibb in 2019, known for its development and commercialization of cancer therapies and other immunology treatments. The Bond issued by Celgen Corporation ( United States ) , in USD, with the ISIN code US151020BB94, pays a coupon of 3.9% per year. The coupons are paid 2 times per year and the Bond maturity is 19/02/2028 The Bond issued by Celgen Corporation ( United States ) , in USD, with the ISIN code US151020BB94, was rated A+ ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
Français
Italiano
United States